Tag: Drug Development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, filing for regulatory status for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

PPD and HLT of China in Exclusive Agreement

Pharmaceutical Product Development, LLC (PPD) and Happy Life Tech (HLT) of China have signed an exclusive agreement to develop a distinctive service offering for the China drug-development market deli...

IQVIA Launches Services for Emerging Biopharma Needs

IQVIA has launched IQVIA Biotech and its new approach to providing clinical and commercial services for small biotech and biopharma companies. The solutions suite will provide simplified operating pro...

GM Chickens Produce Human Proteins

Genetically modified (GM) chickens could be used as a cheaper way to produce certain types of drugs compared to traditional manufacturing methods, research suggests. A team from The University of E...

Aquinnah will Advance Drug Development for Tauopathy

Aquinnah Pharmaceuticals got $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases. In the announcement, the company noted that the ...

Elevian and Insilico to Discover Anti-Aging Drugs

Elevian and Insilico Medicine have announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets. Elevian is an emerging biotech co...

English and Indian Companies Collaboration

agreement
Edinburgh, Scotland-based mental health and neurology research company Caritas Neuro Solutions has signed a landmark partnership agreement with Mumbai, India-based digitally driven organisation Innvoc...

FDA Creates Drug Development Science Office

The FDA will develop more standardized, streamlined, and structured processes for reviewing new drugs, FDA commissioner Dr. Scott Gottlieb announced Tuesday. To do that, the agency will create a ne...

Pfizer will Use CytoReason’s Machine Learning Models for Drug Discovery

pfizer
CytoReason, a leader in machine learning for drug discovery and development, announced that it has entered into a collaboration agreement with Pfizer Inc. that will leverage CytoReason’s cell-centered...

84 Positive Opinions from EMA in 2018

EMA has published an overview of its  recommendations of 2018 on the authorisation and safety monitoring of medicines for human use. New medicines are essential for public health as they can improv...

2018 is Record Breaker for FDA Approvals

As 2019 gets under way, the pharma industry and the US FDA can look back at a truly record-breaking 2018 for new drug approvals. The final tally for novel drug approved at the US regulator last yea...

Intract Gets Grant for Developing Novel Antibody Products

Drug delivery developer Intract Pharma has been awarded a £1.4 million grant by Innovate UK to develop a scalable manufacturing process for novel oral antibody products. The company will develop a ...

Sanofi’s Pediatric Vaccine Approved by FDA

The US Food and Drug Administration (FDA) has approved Sanofi’s pediatric hexavalent combination vaccine for use in children between six weeks and five years of age. The vaccine, called Vaxelis, is...

University of Birmingham Developed New Eye Drop

A group of scientists from the UK’s University of Birmingham has developed a new eye drop that can minimize sight-threatening scarring to the surface of the eye or the cornea. Scars caused by eye i...

Opiant and Sanofi to Develop Drinabant for ACO

Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO). AC...

Xynomic Files 3 IND Applications to Test Abexinostat

Xynomic Pharma, a clinical stage US-China oncology drug development company, today announced that its Trials-in-Progress poster discussing the ongoing, potentially pivotal, phase 3 trial of abexinosta...

Mallinckrodt and NPXe started Phase III trial of xenon gas therapy

mallinckrodt
Mallinckrodt, a global specialty pharmaceutical company, and NPXe Limited confirmed enrollment of the first patient in the pivotal Phase 3 trial of Xenon Gas for Post Cardiac Arrest Syndrome.